Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects

Journal of Clinical Pharmacology

Volumn 38, Issue 3, 1998, Pages 246-255

  Marino, Maria R ^a   Langenbacher, Kathleen ^a   Ford, Neville F ^a   Uderman, Howard D ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b University Medical Center at Princeton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN; PLACEBO;

ADRENERGIC RECEPTOR BLOCKING; ADULT; ALDOSTERONE RELEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG SAFETY; ELECTROLYTE BALANCE; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE BLIND PROCEDURE;

EID: 0031943404     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04422.x     Document Type: Article

References (24)

1. Kang PM, Landau AJ, Eberhardt RT, Frishman WH: Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994;127:1388-1401.
2. Timmermans PBMWM, Smith RD: Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15(suppl D):79-87.
3. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-834.
4. Simon SR, Black HR, Moser M, Berland WE: Cough and ACE inhibitors. Arch Intern Med 1992;152:1698-1700.
5. Christophe B, Libon R, Chatelain P, Manning AS: Effect of SR 47436 on angiotensin II-induced pressor responses in pithed rats (abstract). Br J Pharmacol 1992;105(suppl):259P.
6. 1 receptor antagonist, on blood pressure in primates (abstract). Br J Pharmacol 1993;108(suppl):67P.
7. 1-receptor antagonist, in conscious monkeys. J Hypertens 1993;11:1187-1194.
8. 1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 1994;111:145-150.
9. 1 receptor antagonist in hypertensive rat models. Eur J Pharmacol 1994;264:307-316.
10. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-29.
11. Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF: Pharmacokinetics and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension (abstract). J Hypertens 1996;14:S348.
12. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, et al: The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension (abstract). Am J Hypertens 1996;9:152A.
13. Lasseter KC, Marino MR, Langenbacher KM, Vesterqvist O, Shamblen EC, Ford NF: Pharmacodynamics of irbesartan in subjects with mild-to-moderate hypertension. Am J Hypertens 1997;part 2:A240.
14. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al: Short-term and sustained renal effects of angiojensin II receptor blockade in healthy subjects. Hypertension 1995;25:602-609.
15. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J: Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abstract). J Hypertens 1994;12:88.
16. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R: Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) (abstract). J Hypertens 1994;12:S92.
17. Chang S-Y, Whigan DB, Vachharajani NN, Patel R: A high-performance liquid chromatographic assay for quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J Chromatogr 1997;702:149-155.
18. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL: Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996;28:101-106.
19. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
20. Ogihara T, Nagano M, Mikami H, Higaki J, Kohara K, Azuma J, et al: Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994;16:74-86.
21. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-245.
22. Jusko WJ: Pharmacokinetics of capacity-limited systems. J Clin Pharmacol 1989;29:488-493.
23. Ludden TM: Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 1991;20:429-446.
24. Ribstein J, Sissmann J. Picard A, Bouroudian M, Mimran A: Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects (abstract). J Hypertens 1994;12:131.